Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. 2010

Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
Department of Microbiology and Immunology, Université de Montréal, Montreal, Quebec, Canada.

There is limited knowledge on the identity of primary CD4(+) T cell subsets selectively targeted by HIV-1 in vivo. In this study, we established a link between HIV permissiveness, phenotype/homing potential, and lineage commitment in primary CD4(+) T cells. CCR4(+)CCR6(+), CCR4(+)CCR6(-), CXCR3(+)CCR6(+), and CXCR3(+)CCR6(-) T cells expressed cytokines and transcription factors specific for Th17, Th2, Th1Th17, and Th1 lineages, respectively. CCR4(+)CCR6(+) and CXCR3(+)CCR6(+) T cells expressed the HIV coreceptors CCR5 and CXCR4 and were permissive to R5 and X4 HIV replication. CCR4(+)CCR6(-) T cells expressed CXCR4 but not CCR5 and were permissive to X4 HIV only. CXCR3(+)CCR6(-) T cells expressed CCR5 and CXCR4 but were relatively resistant to R5 and X4 HIV in vitro. Total CCR6(+) T cells compared with CCR6(-) T cells harbored higher levels of integrated HIV DNA in treatment-naive HIV-infected subjects. The frequency of total CCR6(+) T cells and those of CCR4(+)CCR6(+) and CXCR3(+)CCR6(+) T cells were diminished in chronically infected HIV-positive subjects, despite viral-suppressive therapy. A high-throughput analysis of cytokine profiles identified CXCR3(+)CCR6(+) T cells as a major source of TNF-alpha and CCL20 and demonstrated a decreased TNF-alpha/IL-10 ratio in CXCR3(+)CCR6(-) T cells. Finally, CCR4(+)CCR6(+) and CXCR3(+)CCR6(+) T cells exhibited gut- and lymph node-homing potential. Thus, we identified CCR4(+)CCR6(+) and CXCR3(+)CCR6(+) T cells as highly permissive to HIV replication, with potential to infiltrate and recruit more CCR6(+) T cells into anatomic sites of viral replication. It is necessary that new therapeutic strategies against HIV interfere with viral replication/persistence in discrete CCR6(+) T cell subsets.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D054367 Receptors, CXCR3 CXCR receptors that are expressed on the surface of a number of cell types, including T-LYMPHOCYTES; NK CELLS; DENDRITIC CELLS; and a subset of B-LYMPHOCYTES. The receptors are activated by CHEMOKINE CXCL9; CHEMOKINE CXCL10; and CHEMOKINE CXCL11. Antigens, CD183,CD183 Antigens,CXC Chemokine Receptor 3,CXCR3 Receptors,CMKBR3 Chemokine Receptors,CXC Chemokine Receptors 3,CXCR3 Receptor,Chemokine (C-C Motif) Receptor 3,Chemokine Receptors, CMKBR3,Receptor, CXCR3,Receptors, CMKBR3 Chemokine
D054398 Receptors, CCR4 CCR receptors with specificity for CHEMOKINE CCL17 and CHEMOKINE CCL22. They are expressed at high levels in T-LYMPHOCYTES; MAST CELLS; DENDRITIC CELLS; and NK CELLS. Antigens, CD194,CC Chemokine Receptor 4,CCR4 Receptors,CD194 Antigens,CC Chemokine Receptors 4,CCR4 Receptor,CD194 Antigen,Antigen, CD194,Receptor, CCR4

Related Publications

Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
May 2017, Viruses,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
September 2017, Journal of virology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
July 2004, The British journal of dermatology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
January 2004, Journal of virology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
April 1992, Clinical and experimental immunology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
September 2019, Immunology letters,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
June 2016, AIDS (London, England),
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
February 2017, Journal of virology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
May 2023, Retrovirology,
Annie Gosselin, and Patricia Monteiro, and Nicolas Chomont, and Felipe Diaz-Griffero, and Elias A Said, and Simone Fonseca, and Vanessa Wacleche, and Mohamed El-Far, and Mohamed-Rachid Boulassel, and Jean-Pierre Routy, and Rafick-Pierre Sekaly, and Petronela Ancuta
January 2013, Advanced biomedical research,
Copied contents to your clipboard!